Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines

Core Insights - Sanofi and Orano Med have formed a partnership to develop next-generation radioligand medicines targeting rare cancers [1][2] - The collaboration will leverage Orano Med's expertise in targeted alpha therapies and Sanofi's biopharmaceutical capabilities [4][5] Investment and Financials - Sanofi will invest €300 million for a 16% equity stake in the new entity, which is valued at €1.9 billion [8] - This investment aims to accelerate the development of lead-212 based therapies and strengthen Orano Med's pipeline [5][6] Technology and Innovation - The targeted alpha therapy approach combines biological vectors with alpha-emitting radioisotopes to selectively target and destroy cancer cells while minimizing damage to healthy cells [3] - Orano Med has developed a global industrial platform for the reliable and scalable supply of lead-212 based therapies [5][10] Strategic Goals - The partnership aims to advance the treatment of rare cancers and improve patient outcomes through innovative therapies [6][7] - Both companies are committed to contributing to the France 2030 plan to accelerate innovation in oncology [8]